Who are Topiramate; Carbamazepine; Valproate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Topiramate (drug), topiramate, phenytoin, topiramate, propranolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/topiramate-carbamazepine-valproate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Topiramate; Carbamazepine; Valproate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topiramate; Carbamazepine; Valproate (Topiramate; Carbamazepine; Valproate) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsants. Area: Neurology.

phase 3 Anticonvulsants Voltage-dependent sodium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Topiramate; Carbamazepine; Valproate (Topiramate; Carbamazepine; Valproate) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Topiramate is an anticonvulsant that acts as a voltage-dependent sodium channel blocker, whereas Carbamazepine is a tricyclic compound that stabilizes inactivated sodium channels, and Valproate is a fatty acid with anticonvulsant properties.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Topiramate; Carbamazepine; Valproate TARGET	Topiramate; Carbamazepine; Valproate	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Anticonvulsants	Voltage-dependent sodium channels
Topiramate (drug)	Topiramate (drug)	Erasmus Medical Center	phase 3	Sulfamate-substituted monosaccharide	Voltage-dependent sodium channels, GABA receptors
topiramate, phenytoin	topiramate, phenytoin	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Anticonvulsant	Voltage-dependent sodium channels
topiramate, propranolol	topiramate, propranolol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Anticonvulsant	Voltage-dependent sodium channels, GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsants class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topiramate; Carbamazepine; Valproate — Competitive Intelligence Brief. https://druglandscape.com/ci/topiramate-carbamazepine-valproate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab